AS_Hero_Contact

News & Insights

5 min read

The Delta Variant Furin Domain Mutation Favors Greater Infectivity

By Dr. John Kenney on 10/07/2021

The Delta variant has quickly become the predominant strain of SARS-CoV-2. Based on molecular modeling studies, Antibody Solutions was one of the first to propose that the earliest variant, D614G, was more transmissible by promoting furin processing, a key step in virus infection. Consistent with our modeling results, it was later found that a spike protein construct containing the G614 mutation was more susceptible to S1/S2 cleavage by furin. Subsequent SARS-CoV-2 variants have continued to possess the D614G mutation, including the two variants of greatest concern today: Alpha and Delta.

Topics: Covid SARS-CoV-2 Molecuar Modeling antibody discovery COVID-19
6 min read

Functional Assays: Narrowing the Field from Binders to Therapeutic Candidates

By Joshua Lowitz on 06/28/2021

Candidate ID: How to go from hits to lead candidates

We tend to think of antibodies as being defined by their specificity and affinity to a particular antigen. Of equal importance, however, are the functional activities of an antibody upon antigen binding. All are valuable to the discovery of therapeutic antibodies, where the goal is to have a drug that can react with a specific disease target and modify its role in the disease. We describe in this post the types of assays and strategies used to identify the most promising therapeutic antibody candidates.

Topics: antibody discovery Therapeutic Targets immunoassays Functional Assays
1 min read

Original Research: Targeting Three Spike Protein Domains Regulating SARS-CoV-2 Infectivity

By Dr. John Kenney on 05/24/2021

Like our research colleagues across the entire global scientific community, our team here at Antibody Solutions continues to further delve into the complexities of SARS-CoV-2 and its mutations in hopes of further illuminating potential paths for additional discovery work. We presented our most recent findings during the 2021 PEGS Boston Virtual Conference & Expo.

Topics: Insights Covid SARS-CoV-2 Molecuar Modeling COVID-19
4 min read

Peptides: The Less-is-More Strategy for Success

By Jennifer Somera on 05/06/2021

A strategic approach to peptide design yields success

When deciding which antigens to use for an antibody discovery project, there are many available options. Peptides, which have been around for at least 60 years, are one way in.  Other — and, in many cases, newer — available paths include recombinant proteins, engineered cells and DNA coding for the protein. 

Topics: News Insights SARS-CoV-2 antibody discovery peptides
7 min read

Animals are Still Vital for Antibody Discovery

By Dr. John Kenney on 04/05/2021

If the last year has taught us anything, it’s that major biological threats can emerge seemingly out of nowhere, causing death and disruption on a global scale. We watched the international scientific community combine all its forces to quickly and effectively mount a response to the novel biological threat of SARS-CoV-2. Key to that response was the immunization of animals, enabling the generation of reagent and therapeutic antibodies as well as development of vaccines. It was an accelerated, and very public, demonstration of the power of in vivo antibody generation that has been applied to discover therapies for cancer, autoimmune diseases, and other ailments.

Topics: Insights antibody discovery
4 min read

Getting your antigen to stand out in the crowd

By Michael Trang on 03/16/2021

Here at Antibody Solutions, we believe that starting with the best possible input will yield the best possible output. A critical input for any antibody discovery program is the immunogen; i.e., what will be administered to the host animal to raise an antibody response? While it may seem complex, intact cells bearing your target antigen may be the best input. We explore that subject in this blog post through a series of frequently asked questions from our clients.

Topics: Insights Transgenic Animals antigen syngeneic
5 min read

Cell Fusion: A trusted tool that can still be an enigma

By Joshua Lowitz on 02/24/2021

“Mystery is at the heart of creativity. That, and surprise.”  Julia Cameron

Topics: Insights Hybridoma cell fusion
2 min read

Modeling the Impact of the UK and South African Strain Mutations

By Dr. John Kenney on 02/09/2021

Mutations Found in the South African and UK COVID-19 Virus Strains Improve the Stability of the ACE2-Spike RBD Complex

Topics: Insights Covid SARS-CoV-2 Molecuar Modeling COVID-19
1 min read

Original Research: Generating Antibodies to SARS-CoV-2 Spike Protein Sites

By Dr. John Kenney on 01/19/2021

As we’ve noted in some recent blog posts (here and here, for instance), our team at Antibody Solutions is joining the global scientific community in the collective fight against SARS-CoV-2 and its mutations. That includes both research conducted on behalf of our clients and our own discoveries. 

Topics: News Insights Covid SARS-CoV-2 Molecuar Modeling COVID-19
5 min read

Measure Twice, Cut Once: The Value of Target Analysis in Antibody Discovery

By Joshua Lowitz on 01/12/2021

Editor’s note: Welcome to 2021, and to our first in a year-long series of posts that will explore the essentials in antibody discovery. We’re starting off with a frequently under-appreciated technique for getting to “yes” or “no” faster — target analysis. Next up, in early February, we’ll be talking about fusions. Thanks for reading, and we invite your ideas on what you consider to be “the essentials” of antibody research success.

Topics: Insights Therapeutic Targets target analysis immunogens
2 min read

The UK Strain and Other Recent RBD Mutations in the SARS-CoV-2 Virus

By Dr. John Kenney on 12/22/2020

Examining mutations in the SARS-CoV-2 Spike (S) Protein Receptor Binding Domain (RBD) at the ACE2 receptor S protein interface

Topics: News Insights Covid SARS-CoV-2 Molecuar Modeling COVID-19
5 min read

COVID-19 Targets, Tools and Therapeutics (Part 2)

By Dr. John Kenney on 12/15/2020

Antibody Solutions is doing its part to respond to the COVID-19 pandemic, including original research, tool discovery, and participation in in-house and client-sponsored discovery programs. In this new blog series, we examine questions such as: What are the potential targets to treat COVID-19 and its sequelae, and what are the strategies and tools to discover drugs to treat the disease?

Topics: Insights Covid SARS-CoV-2 Molecuar Modeling Transgenic Animals COVID-19
4 min read

Expanding the Repertoire of Antibody Drug Discovery with Lambda Light-Chain Models

By Joshua Lowitz on 11/30/2020

Accessing the Untapped Potential of 33% of Human IgG

Topics: Transgenic Animals Lambda Mouse lambda light chain
3 min read

Global Spotlight Shines on mRNA Thanks to Pfizer, BioNTech COVID-19 Vaccine Candidate

By Debra Valsamis on 11/11/2020

In the science shot heard ‘round the world, Pfizer and BioNTech announced Monday that their vaccine candidate (aka “BNT162b2”) appears to be more than 90% effective in preventing SARS-CoV-2 among those without evidence of prior infection. And since that news broke on the same day that the number of confirmed U.S. cases of COVID-19 crossed yet another grim threshold — 10 million infected — it couldn’t have come at a better time.

Topics: Insights Covid SARS-CoV-2 COVID-19 mRNA
3 min read

COVID-19 Targets, Tools and Therapeutics (Part 1)

By Dr. John Kenney on 10/14/2020

Antibody Solutions is doing its part to respond to the COVID-19 pandemic, including original research, tool discovery, and participation in in-house and client-sponsored discovery programs. In this new blog series, we examine questions such as: What are the potential targets to treat COVID-19 and its sequelae, and what are the strategies and tools to discover drugs to treat the disease?

Topics: Insights Covid SARS-CoV-2 Molecuar Modeling COVID-19
4 min read

Women Helping Women Power Through the Pandemic

By Judith Lynch-Kenney on 08/24/2020

On July 30th, we had the pleasure of moderating a virtual panel on Antibody Discovery and the Pandemic for the San Francisco Bay Area Chapter of Women in Bio (an event I joined via Zoom from our new headquarters in Santa Clara). At the beginning of 2020, our goal here at Antibody Solutions was to host a networking and professional development event on the last Thursday of each month: January was our grand opening . . . February was our inaugural “Bits, Bites and Brews” event . . . and March was, well, you can guess what happened there.

Topics: Insights women in bio
6 min read

News Release: Study Identifies Potential COVID Vaccine & Therapy Research Pathways

By Dr. John Kenney on 06/17/2020

Conformational change of the spike protein furin cleavage domain may enhance virus infectivity

June 16, 2020 (Santa Clara, Calif.) — Research by two U.S.-based antibody discovery companies shows a rise and dominance of a mutant SARS-CoV-2 virus and identifies a new mechanism predicting a competitive advantage of the mutation. The mutation is predicted to induce a structural change in the spike protein of the virus that would enhance virus entry. The study, conducted by Antibody Solutions and Single Cell Technology (SCT), is available on Preprints.org (the study’s findings have not yet been peer-reviewed).

Topics: News Covid SARS-CoV-2 Molecuar Modeling COVID-19
7 min read

Original Research: Joint effort finds advantages conferred by a D614G mutation in the SARS-CoV-2 spike protein

By Dr. John Kenney on 06/05/2020

It’s not often that small biotechnology companies pursue basic research into disease mechanisms. However, the serious impact of the SARS-CoV-2 outbreak on our families, friends, and community has prompted us to seek solutions for solving the COVID-19 pandemic. At Antibody Solutions (AS) and Single Cell Technology (SCT), we sought answers to the nature of the virus infection using our tools at hand.

Topics: Insights Covid SARS-CoV-2 Molecuar Modeling COVID-19
5 min read

Antibody Solutions & the COVID-19 Crisis

By Dr. John Kenney on 04/19/2020

EDITOR'S NOTE: We're thankful to be holding true to the potential we outlined in this original April 19 blog post. As part of a collaboration with Single Cell Technology, we've discovered a potential new path for SARS-CoV-2 vaccine and therapy research. We've published our findings in a new paper, and you can get an overview here (as well as a link to the complete research document).


 

“It must be noted, however, that a single product is unlikely to meet the currently very substantial medical need, and not all product candidates will be successful in clinical studies. Therefore, many initiatives aimed at developing investigational antibodies are needed.”

— Dr. Janice Reichert, executive director, The Antibody Society

Where We Stand Now: The bottom line up-front

It’s probably safe to assume that—for all the wrong reasons—”coronavirus” will be Merriam-Webster’s word of the year for 2020. 

Topics: Insights Covid SARS-CoV-2 therapeutic monoclonal antibodies Therapeutic Targets COVID-19
1 min read

Antibody Solutions COVID-19 Update #2

By Dr. John Kenney on 04/02/2020

UPDATED 4/2/2020

On March 31, 2020, California Gov. Gavin Newsom extended the statewide shelter-in-place order through May 3, 2020. Additional restrictions designed to help protect citizens from the COVID-19 pandemic also were imposed.

Consistent with the March 19 order, this order considers life science companies such as Antibody Solutions to be “essential,” meaning we are exempt from many restrictions imposed on other businesses and can continue our operations. As specified in this order, we are preparing an updated document formalizing the social distancing protocol we had implemented in accordance with the first order.

Topics: News Covid COVID-19
1 min read

Antibody Solutions COVID-19 Update #1

By Dr. John Kenney on 03/17/2020

UPDATED 3/20/2020

On March 19, 2020, California Gov. Gavin Newsom announced statewide requirements in light of the COVID-19 pandemic. These required actions in this order align with the Santa Clara County shelter-in-place orders released earlier this week and have not imposed any additional restrictions on Antibody Solutions operations. We will continue to monitor this situation and provide updates, as necessary.  

On March 16, 2020, the Public Health Department of Santa Clara County, California, along with five other San Francisco Bay Area counties, issued a shelter-in-place order for all county residents in response to the COVID-19 pandemic. That includes us here at Antibody Solutions.

Topics: News Covid COVID-19
6 min read

"The secret of life is enjoying the passage of time": Dr. John Kenney's Grand Opening Remarks

By Debra Valsamis on 02/10/2020

On January 30, 2020, Antibody Solutions held a celebration to commemorate both of our new expanded facility in Santa Clara, Calif., and our 25th anniversary,  As part of the event, the company's president and co-founder, Dr. John Kenney, delivered a compelling and inspiring keynote address to our valued guests. In addition to recognizing and thanking all of our employees, clients and friends through the years, John offered his perspectives on the growth and progress of Antibody Solutions since our founding in 1995 and shared some "lessons learned" from his career that he believes will guide our success for next 25 years. His remarks are included below. 

Topics: Insights 25th Anniversary
3 min read

Come Together, Right Now—For What Could Be

By Dr. John Kenney on 02/06/2020

Antibody Solutions’ Grand Opening Celebration | 01.30.20

From sparkling selfies and twirling mobiles of antibodies to insightful speeches, facility tours and tasty tacos, Antibody Solutions’ Grand Opening celebration last week had a little bit of everything. And we couldn’t be prouder!(*)

More than 125 treasured clients, partners and their families came together for what could be--and was—an evening of fun, festivity and friendship. We held the event to commemorate both our new 33,300-square-foot facility in Santa Clara, Calif., and the kickoff to our Silver Anniversary. The theme for our event was “25 Years of Revealing the Future,” and it was especially wonderful to welcome many guests who’ve been with us through the decades. 

Topics: News 25th Anniversary
1 min read

Webinar: “Using Fluorescence-Activated Cell Sorting (FACS) for B-Cell Isolation”

By Dr. John Kenney on 11/13/2019

Isolating B cells can be a challenging exercise requiring careful planning, precise execution and the right technology. Over the years, the best method that we’ve found to help streamline and improve the efficiency and success of the process is Fluorescence-Activated Cell Sorting (FACS). 

Topics: Insights
5 min read

Connecting the Dots: Discovery On Target 2019 Wrap-Up

By Dr. John Kenney on 10/18/2019

After a couple weeks of tackling the tsunami of emails, meetings and project updates that greeted me after my two-week “conference marathon” in Boston last month, here is a summary of Discovery on Target 2019. And, like the CAR-TCR Summit the week before, this year’s DOT (#17 in the series) offered a wide range of useful and interesting updates on the latest in antibody research.

Topics: Insights
3 min read

Already Strong & Gaining Momentum: CAR-TCR Summit 2019 Wrap-Up

By Dr. John Kenney on 10/17/2019

You know, it’s true -- there’s no place like home (especially Antibody Solutions’ new home in Santa Clara, California). At the same time, though, I probably would have stayed another week in Boston had there been a third conference that was as chock full of engaging presentations, intriguing research and useful data (plus some very stimulating hallway conversations) as the two back-to-back conferences I attended earlier this month: CAR-TCR Summit 2019 and Discovery on Target 2019.  

Topics: Insights
5 min read

CAR-T Cell Therapy 101

By Dr. John Kenney on 08/29/2019

Chimeric antigen receptor (CAR-T) cell therapy

A growing number of CAR-T cell therapies are being developed and tested in clinical studies as an innovative approach to reprogram the patient’s immune system to attack its own abnormal cells. For treatment of certain cancers, as well as other diseases, this is a huge leap forward. 

Topics: Insights
3 min read

Climbing for a Crucial Cause - Part 3

By Dr. John Kenney on 08/14/2019

Editor’s Note: This is the third and final post in a series on Dr. Oren Beske of ATUM and his climb up Mt. Kilimanjaro in support of the Fred Hutchinson Cancer Research Center. In an effort to avoid spoiling his inspiring last installment, we’ll just invite you to catch up on Oren’s first and second posts and then jump right in below.

Our thanks and congratulations to Oren and to all of you for supporting this terrific initiative! 

John Kenney

Co-Founder and CEO, Antibody Solutions

Topics: Insights
4 min read

Climbing for a Crucial Cause - Part 2

By Dr. John Kenney on 07/15/2019

Editor’s Note: Here’s the second installment in a blog post series we’re excited to present in conjunction with our friend and colleague Dr. Oren Beske of ATUM. If you missed Oren’s first post on his climb to help the Fred Hutchinson Cancer Research Center, you can read it here.

Thanks for continuing this journey with us. Onward and, more importantly, upward!

John Kenney

Co-Founder and CEO, Antibody Solutions

Topics: Insights
2 min read

The Promising Potential of CAR-T Therapy

By Billy Nguyen on 07/05/2019

Post-Show Perspectives: Next-Generation CAR and T Cell Therapies
June 18-20, 2019 | Park Central Hotel, San Francisco, Calif. 

A few weeks ago, a group of us from Antibody Solutions headed up the highway from Sunnyvale (our old home) to San Francisco where we attended the “Next-Generation CAR and T Cell Therapies” conference. In short, the event was well worth the investment of time, and we look forward to participating in similar conferences in the future. 

Topics: Insights
3 min read

Climbing for a Crucial Cause

By Dr. John Kenney on 06/28/2019

Editor’s Note: We’re proud to present our first in a series of reflections from our friend and colleague, Dr. Oren Beske of ATUM. We think you’ll find the journey he’s on—one that’s both acutely personal yet wholly universal—to be inspiring and thought-provoking. At Antibody Solutions, we share the end goal of our oncology drug development partners and clients: To extend the quality and quantity of life for cancer patients, and, once and for all, to pitch cancer headfirst into the dustbin of medical history. We salute Oren and all those supporting the Fred Hutchinson Cancer Research Center (or, in shorthand, “Fred Hutch”). Climb well! 

Topics: Insights
2 min read

Expanded Partnership Offers Antibody Solutions Clients Access to the Transgenic H2L2 Harbour Mice™ Platform

By Dr. John Kenney on 05/16/2019

  

Agreement Provides for Easy Access to the Transgenic H2L2 Harbour Mice™ Platform with Antibody Solutions’ Discovery and Development Services

Topics: News Transgenic Animals transgenic H2L2 mice Harbour
2 min read

A New Way to Solve Problematic Rat IgG Purification

By Dr. John Kenney on 05/10/2019


When you think about the rat IgG production and purification process (especially IgG2a), what words often come to mind? If you’re like most researchers, it’s probably a combination of these: frustration, missed timelines, low purity, and poor recovery.

Topics: Insights Transgenic Animals Monoclonal therapeutic monoclonal antibodies OmniRat igG MAbExpress IgG purification
3 min read

PEGS  Boston 2019 Takeaways

By Dr. John Kenney on 04/24/2019

What do you get when you inject 2,600 participants into more than 400 sessions, 300-plus research posters and more than 150 exhibitors and then put ‘em all next to Boston Harbor for a week?

Topics: Insights
2 min read

PEPTALK 2019 Wrap-Up: Where the Deep Sequencing Repertoire Fits In

By Michael Trang on 04/02/2019

PepTalk 2019: The Protein Science Week
January 14-18, 2019 | San Diego Hilton Bayfront, San Diego, Calif.

Topics: Insights
2 min read

Keystone Joint Symposia Wrap-Up: A “Two-for-One” Win

By Dr. John Kenney on 03/07/2019

Earlier this month, I had the good fortune to attend the “Keystone Joint Symposia” event in Keystone, Colo. (and yes, it was much colder than at Antibody Solutions’ headquarters in Sunnyvale, Calif.!).The speakers during the sessions had two primary goals: (1) to present the most recent advances in the biology of T cell-dependent B cell responses; and (2) to explore how our understanding of B-T cell interactions influence antibody generation and inform vaccine development.

Topics: Insights
1 min read

Success Rate of Different Antibody Platforms for Drug Discovery

By Dr. John Kenney on 03/07/2019

We are occasionally asked about the success rate of different antibody platforms for drug discovery. There are a variety of technologies available for therapeutic antibody discovery: conventional mice where the Abs are humanized, human Ab transgenic rodents, human Ab synthetic phage and yeast libraries, and others.

Topics: Insights
1 min read

Molecular Approaches to Vaccines and Immune Monitoring 2019

By Marketing on 03/07/2019

Antibody Solutions will be attending Keystone Symposia's Molecular Approaches 2019, to be held February 10-15 in Keystone, CO.

Topics: Events
1 min read

PEGS 2019

By Marketing on 03/07/2019

Antibody Solutions will be attending PEGS 2019, to be held April 8-12 in Boston, MA.

Topics: Events
1 min read

Next Gen CAR-T 2019

By Marketing on 03/07/2019


Antibody Solutions will be attending Next Generation CAR & T Cell Therapies 2019, to be held June 18-20 in San Francisco, CA.

Topics: Events CAR-T Cell therapy
1 min read

CAR-TCR Summit 2019

By Marketing on 03/07/2019

Antibody Solutions will be attending CAR-TCR Summit 2019, to be held September 10-13 in Boston, MA.

Topics: Events
1 min read

Discovery On Target 2019

By Marketing on 03/07/2019

Antibody Solutions will be attending Discovery On Target 2019, to be held September 17-19 in Boston, MA.

Topics: Events
1 min read

PEGS Europe 2019

By Marketing on 03/07/2019

Antibody Solutions will be attending PEGS Europe 2019, to be held November 18-22 in Lisbon, Portugal.

Topics: Events
1 min read

Antibody Engineering 2019

By Marketing on 03/07/2019

Antibody Solutions will be attending Antibody Engineering & Therapeutics 2019, to be held December 9-13 in San Diego, CA.

Topics: Events
1 min read

PEPTALK 2019

By Marketing on 01/02/2019

Antibody Solutions will be attending PepTalk 2019, to be held January 14-18 in San Diego, CA.

Topics: Events
2 min read

Antibody Solutions Announces Partnership with SCT at 2017 Antibody Engineering & Therapeutics Conference

By Debra Valsamis on 12/11/2017

Antibody Solutions, a leader in discovery of therapeutic, biomarker and critical reagent antibodies, and Single Cell Technology, Inc. (SCT), a pioneer in single cell analysis technology, have launched a partnership that offers pharmaceutical researchers one-stop access to advanced single B-cell antibody discovery capabilities.

Topics: News